Non-comparative, open phase III study assessing the efficacy and tolerance of collagenase clostridium histolyticum in patients with Dupuytren's contracture
Latest Information Update: 18 Jun 2014
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Dupuytren's contracture
- Focus Registrational; Therapeutic Use
Most Recent Events
- 08 May 2014 According to a Biospecifics Technologies Corporation media release, the supplement biologics license application (sBLA) for potential label expansion of Xiaflex is under FDA review with a PDUFA date of October 20, 2014.
- 22 Oct 2013 New trial record